PE20001467A1 - Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina - Google Patents

Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina

Info

Publication number
PE20001467A1
PE20001467A1 PE2000000125A PE0001252000A PE20001467A1 PE 20001467 A1 PE20001467 A1 PE 20001467A1 PE 2000000125 A PE2000000125 A PE 2000000125A PE 0001252000 A PE0001252000 A PE 0001252000A PE 20001467 A1 PE20001467 A1 PE 20001467A1
Authority
PE
Peru
Prior art keywords
alkyl
phenylpyridine
derivatives
alcoxy
trifluoromethyl
Prior art date
Application number
PE2000000125A
Other languages
English (en)
Spanish (es)
Inventor
Quirico Branca
Michael Bos
Guido Galley
Heinz Stadler
Torsten Hoffmann
Walter Hunkeler
Patrick Schnider
Thierry Godel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20001467A1 publication Critical patent/PE20001467A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2000000125A 1999-02-24 2000-02-18 Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina PE20001467A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99103504 1999-02-24
EP99123689 1999-11-29

Publications (1)

Publication Number Publication Date
PE20001467A1 true PE20001467A1 (es) 2000-12-20

Family

ID=26152908

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000125A PE20001467A1 (es) 1999-02-24 2000-02-18 Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina

Country Status (54)

Country Link
US (2) US6297375B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EP (2) EP1035115B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JP (1) JP3399900B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
KR (1) KR100384904B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CN (1) CN1142144C (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AR (2) AR029614A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AT (2) ATE277905T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
AU (1) AU767048B2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BE (1) BE2015C057I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BG (1) BG64554B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
BR (1) BRPI0000908B8 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CA (1) CA2299139C (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CY (3) CY1111317T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
CZ (1) CZ300596B6 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
DE (3) DE60045564D1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
DK (2) DK1035115T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EA (1) EA003673B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
EG (1) EG23817A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
ES (3) ES2226622T3 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
FR (2) FR2790473B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
GB (1) GB2347422A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
GE (1) GEP20022676B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
GT (1) GT200000017A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HR (2) HRP20000097B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
HU (1) HU227629B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
IL (1) IL134654A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
IS (1) IS2116B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
IT (1) IT1320763B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
JO (1) JO2294B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
LT (1) LTC1035115I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
LU (1) LU92745I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MA (1) MA26722A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
ME (1) ME00593B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
MY (2) MY147451A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
NL (1) NL300758I1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
NO (1) NO315554B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
NZ (1) NZ502948A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
OA (1) OA11680A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PA (1) PA8491101A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PE (1) PE20001467A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PL (1) PL217311B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
PT (2) PT1394150E (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
RS (3) RS53869B1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SE (1) SE1035115T5 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SG (1) SG91856A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SI (1) SI1035115T1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SK (2) SK287911B6 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
SV (1) SV2002000024A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
TN (1) TNSN00032A1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
TR (1) TR200000520A2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
TW (1) TWI288746B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
UA (1) UA71547C2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
UY (1) UY32314A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)
ZA (1) ZA200000894B (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058640A2 (en) * 1998-05-11 1999-11-18 Philadelphia Health And Education Corporation Mct-1, a human oncogene
IL144717A0 (en) 1999-02-24 2002-06-30 Hoffmann La Roche Phenyl-and pyridinyl derivatives
US6291465B1 (en) * 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
US6303790B1 (en) 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
DE60006340T2 (de) * 1999-11-29 2004-09-09 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramid
AUPQ514600A0 (en) * 2000-01-18 2000-02-10 James Cook University Brain injury treatment
JP3938651B2 (ja) * 2000-04-13 2007-06-27 ă‚»ăƒłăƒˆăƒ©ăƒ«çĄć­æ ȘćŒäŒšç€Ÿ ć…‰ć­ŠæŽ»æ€§Î±âˆ’ăƒĄăƒăƒ«âˆ’ăƒ“ă‚čâˆ’ïŒ“ă€ïŒ•âˆ’ïŒˆăƒˆăƒȘăƒ•ăƒ«ă‚Șăƒ­ăƒĄăƒăƒ«ïŒ‰ăƒ™ăƒłă‚žăƒ«ă‚ąăƒŸăƒłăźèŁœé€ æ–čæł•
SI1303490T1 (sl) 2000-07-14 2008-10-31 Hoffmann La Roche N-oksidi kot predzdravila NK 1 receptorskega antagonista 4-fenil-piridin derivatov
TWI287003B (en) 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
PT1349541E (pt) 2000-12-14 2007-01-31 Hoffmann La Roche Matriz lipĂ­dica auto-emulsionante (selm)
US6531597B2 (en) * 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
JP4225787B2 (ja) * 2001-03-27 2009-02-18 ă‚šăƒŒă‚¶ă‚€ăƒ»ă‚ąăƒŒăƒ«ăƒ»ă‚ąăƒłăƒ‰ăƒ»ăƒ‡ă‚ŁăƒŒăƒ»ăƒžăƒă‚žăƒĄăƒłăƒˆæ ȘćŒäŒšç€Ÿ ïŒźâˆ’ă‚ąăƒȘăƒŒăƒ«ç’°çŠ¶ă‚ąăƒŸăƒłèȘ˜ć°Žäœ“ăŠă‚ˆăłăă‚Œă‚’æœ‰ćŠčæˆćˆ†ăšă—ăŠć«æœ‰ă™ă‚‹ćŒ»è–Ź
DE60210760T2 (de) * 2001-04-23 2006-11-23 F. Hoffmann-La Roche Ag Verwendung von nk-1-rezeptorantagonisten gegen benigne prostatahyperplasie
DK2266558T3 (en) * 2001-06-07 2017-07-31 Analgesic Neuropharmaceuticals Llc TREATMENT OF NEUROPATHIC PAIN WITH RECEPTOR ANTAGONIST: N-METHYL-D-ASPARTATE (NMDA)
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
PL202691B1 (pl) * 2001-09-10 2009-07-31 Hoffmann La Roche Tiksotropowa oleista zaróbka, sposób jej wytwarzania, masa wypeƂniająca do kapsuƂek i farmaceutyczna jednostkowa postać dawkowana
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
BR0314126A (pt) 2002-09-20 2005-06-28 Pfizer Prod Inc Ligandos de amida acĂŹclica e sulfonamida para o receptor de estrogĂȘnio
US7244748B2 (en) * 2002-12-06 2007-07-17 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
US8729107B2 (en) * 2002-12-06 2014-05-20 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
NZ541243A (en) 2003-01-31 2008-04-30 Hoffmann La Roche New crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1lambda6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
BRPI0412291A (pt) * 2003-07-03 2006-09-19 Hoffmann La Roche antagonistas duplos de nka/nk3 para o tratamento de esquizofrenia
TWI280239B (en) 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
TW201038270A (en) 2003-07-30 2010-11-01 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use in the inhibition of stearoyl-CoA desaturase
CN1997371A (zh) * 2004-07-06 2007-07-11 æłœć†œćŒ»èŻć…Źćž 烟酰èƒșèĄç”Ÿç‰©ćŠć…¶äœœäžșæȻ疗扂的甚途
CA2572645C (en) * 2004-07-06 2011-01-18 F. Hoffmann-La Roche Ag Process for preparing carboxamide derivatives used as intermediates in the synthesis of nk-1 receptor antagonists
KR100881240B1 (ko) * 2004-07-06 2009-02-05 에프. 혾프만-띌 ëĄœìŠˆ 아êȌ ïŒźïœ‹-1 수용ìČŽ Ꞟ항제의 합성에 있얎서 쀑간ìČŽëĄœì„œì‚Źìš©ë˜ëŠ” ìčŽë„Žëł”ìŠ€ì•„ëŻžë“œ í”ŒëŠŹë”˜ 유도ìČŽì˜ ì œìĄ° ë°©ëȕ
WO2006013205A1 (en) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation
US20060030556A1 (en) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation, including testosterone deficiency
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
CN101083982A (zh) 2004-09-20 2007-12-05 æłœć†œćŒ»èŻć…Źćž 甹äșŽæČ»ç–—çĄŹè„‚é…°CoAćŽ»é„±ć’Œé…¶ä»‹ćŻŒçš„ç–Ÿç—…çš„æ‚çŽŻèĄç”Ÿç‰©
AU2005329423A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP1799664A1 (en) 2004-09-20 2007-06-27 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
TW200626155A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
AR051092A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa
MX2007003321A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
US7569725B2 (en) * 2004-10-21 2009-08-04 Britsol-Myers Squibb Company Anthranilic acid derivatives as inhibitors of 17ÎČ-hydroxysteroid dehydrogenase 3
WO2006060174A1 (en) * 2004-11-15 2006-06-08 Honeywell International Inc. Isocyanate-based polymer foams with nano-scale materials
MX2007010034A (es) * 2005-02-22 2007-10-04 Hoffmann La Roche Antagonista de nk1.
CN101128428A (zh) * 2005-02-24 2008-02-20 è©čæŁźèŻäžšæœ‰é™ć…Źćž 䜜äžșé’ŸçŠ»ć­é€šé“æ‰“ćŒ€ć‰‚çš„æ–°çš„ćĄć•¶èĄç”Ÿç‰©
EP1855655A2 (en) 2005-02-25 2007-11-21 F. Hoffmann-Roche AG Tablets with improved drug substance dispersibility
PT1863767E (pt) 2005-03-23 2009-03-27 Hoffmann La Roche Metabolitos para antagonistas de nk-1 para vĂłmitos
CN101208089A (zh) 2005-06-03 2008-06-25 æłœć†œćŒ»èŻć…Źćž æ°šćŸșć™»ć”‘èĄç”Ÿç‰©äœœäžșäșș硬酯酰-CoAćŽ»é„±ć’Œé…¶æŠ‘ćˆ¶ć‰‚
ATE512145T1 (de) * 2005-08-11 2011-06-15 Vertex Pharma Modulatoren des cystic fibrosis transmembrane conductance regulators
CN101305011B (zh) 2005-09-09 2011-03-02 ćČćŻ†äžć…‹èŽ±æ©æŻ”ćœ»ć§†ć…Źćž ćĄć•¶èĄç”Ÿç‰©ćŠć…¶ćœšæȻ疗çČŸç„žéšœçąäž­çš„ç”šé€”
PL1928427T3 (pl) * 2005-09-23 2010-06-30 Hoffmann La Roche Nowa postać dawkowana
EP1945632B1 (en) * 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7872022B2 (en) * 2006-04-03 2011-01-18 Hoffmann-La Roche Inc. Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
IN2014KN02423A (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2006-04-07 2015-05-01 Vertex Pharma
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
CN104447716A (zh) 2007-05-09 2015-03-25 æČƒæł°ć…‹æ–ŻèŻç‰©è‚Ąä»œæœ‰é™ć…Źćž Cftrè°ƒèŠ‚ć‰‚
PT2225230T (pt) 2007-12-07 2016-12-07 Vertex Pharma Formas sĂłlidas de ĂĄcido 3-(6(1-(2,2-difluorobenzo[d][1,3] dioxol-5-il) ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico
MX364936B (es) 2007-12-07 2019-05-15 Vertex Pharma Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
WO2009105498A1 (en) * 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
NZ720282A (en) 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0814340D0 (en) 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
EA021411B1 (ru) * 2009-08-27 2015-06-30 ĐĐ”Ń€Ń€ ĐąĐ”Ń€Đ°ĐżŃŒŃŽŃ‚ĐžĐșс Đ›ĐžĐŒĐžŃ‚Đ”ĐŽ БДзĐČĐŸĐŽĐœĐ°Ń Ń„ĐŸŃ€ĐŒĐ° ĐżŃ€ĐŸĐžĐ·ĐČĐŸĐŽĐœĐŸĐłĐŸ ĐżĐžŃ€ĐžĐŽĐžĐœĐ°
EP2727590B1 (en) 2009-11-18 2015-10-21 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
TW201143768A (en) * 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RU2579370C2 (ru) 2010-04-07 2016-04-10 ВДртДĐșс Đ€Đ°Ń€ĐŒĐ°ŃŃŒŃŽŃ‚ĐžĐșалз Đ˜ĐœĐșĐŸŃ€ĐżĐŸŃ€Đ”ĐčтДЎ ĐąĐČДрЎыД Ń„ĐŸŃ€ĐŒŃ‹ 3-(2, 2-ĐŽĐžŃ„Ń‚ĐŸŃ€Đ±Đ”ĐœĐ·ĐŸ[d][1, 3] ĐŽĐžĐŸĐșŃĐŸĐ»-5-Ол)цоĐșĐ»ĐŸĐżŃ€ĐŸĐżĐ°ĐœĐșĐ°Ń€Đ±ĐŸĐșŃĐ°ĐŒĐžĐŽĐŸ)-3-ĐŒĐ”Ń‚ĐžĐ»ĐżĐžŃ€ĐžĐŽĐžĐœ-2-Ол)Đ±Đ”ĐœĐ·ĐŸĐčĐœĐŸĐč ĐșĐžŃĐ»ĐŸŃ‚Ń‹
EP3150198B1 (en) 2010-04-07 2021-09-22 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
NZ734535A (en) 2010-04-22 2019-05-31 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
EP2747560A4 (en) * 2011-07-29 2015-02-25 Tempero Pharmaceuticals Inc CONNECTIONS AND METHODS
EP2736329A4 (en) * 2011-07-29 2015-03-25 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
US9358228B2 (en) 2011-10-18 2016-06-07 Helsinn Healthcare Sa Therapeutic combinations of netupitant and palonosetron
JP6072056B2 (ja) 2011-11-08 2017-02-01 ăƒăƒŒăƒ†ăƒƒă‚Żă‚č ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ïŒ¶ïœ…ïœ’ïœ”ïœ…ïœ˜   ïŒĄïœ”ïœâˆ’ç”ćˆă‚«ă‚»ăƒƒăƒˆăƒˆăƒ©ăƒłă‚čăƒăƒŒă‚żăƒŒăźäżźéŁŸć› ć­
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
AR092857A1 (es) 2012-07-16 2015-05-06 Vertex Pharma Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
WO2015068744A1 (ja) * 2013-11-08 2015-05-14 ă‚­ăƒƒă‚»ă‚€è–Źć“ć·„æ„­æ ȘćŒäŒšç€Ÿ ă‚«ăƒ«ăƒœă‚­ă‚·ăƒĄăƒăƒ«ăƒ”ăƒšăƒȘゾンèȘ˜ć°Žäœ“
NZ720958A (en) 2013-11-12 2022-02-25 Vertex Pharma Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
HUE055369T2 (hu) 2014-04-15 2021-11-29 Vertex Pharma Gyógyåszati készítmények cisztås fibrózis transzmembrån konduktancia regulåtor kövzetítette betegségek kezelésére
WO2015171489A1 (en) * 2014-05-05 2015-11-12 Apicore Us Llc Methods of making netupitant and intermediates thereof
TWI649307B (zh) 2014-05-07 2019-02-01 æ—„ć•†æ©˜ç”Ÿè—„ć“ć·„æ„­è‚Ąä»œæœ‰é™ć…Źćž Cyclohexylpyridine derivative
TW201613888A (en) * 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
AU2015350049B2 (en) 2014-11-18 2021-08-19 Vertex Pharmaceuticals Incorporated Process of conducting high throughput testing high performance liquid chromatography
MX385788B (es) 2015-03-04 2025-03-18 Vanda Pharmaceuticals Inc MĂ©todo de tratamiento con tradipitant.
CN105061303A (zh) * 2015-08-03 2015-11-18 æˆéƒœæŹŁæ·é«˜æ–°æŠ€æœŻćŒ€ć‘æœ‰é™ć…Źćž äž€ç§ćˆ¶ć€‡ć„ˆćŠ„ćĄćŠć…łé”źäž­é—Žäœ“n-ç”ČćŸș-4-(2-ç”ČćŸșè‹ŻćŸș)-6-(4-ç”ČćŸș-1-擌ć—ȘćŸș)-3-搥敶èƒș的新æ–čæł•
EP4019018A1 (en) 2015-09-11 2022-06-29 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
EP3388423B1 (en) 2015-12-07 2020-05-27 Kissei Pharmaceutical Co., Ltd. Nk1 receptor antagonist
TW202246215A (zh) 2015-12-18 2022-12-01 çŸŽć•†äșžćŸ·ćˆ©ć…‹æ–Żć…Źćž 䜜ç‚ș非慹èș«ïœ”ïœ‡ïœ’ïŒ•äżƒæ•ˆćŠ‘äč‹ç¶“ć–ä»Łäč‹ïŒ”ïŒè‹ŻćŸșćĄć•¶ćŒ–ćˆç‰©
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
CN106892864A (zh) * 2015-12-21 2017-06-27 äžŠæ”·ç§‘èƒœèŻç‰©ç ”ć‘æœ‰é™ć…Źćž äž€ç§ć„ˆćŠ„çšźćŠæžžçŠ»çą±çš„æ™¶ćž‹aćŠć…¶ćˆ¶ć€‡æ–čæł•
AU2016377658B2 (en) * 2015-12-22 2022-09-29 Endosome Therapeutics, Inc. Tripartite modulators of endosomal G protein-coupled receptors
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
KR20250069704A (ko) 2017-06-30 2025-05-19 ìČŽìŽìŠ€ 테띌퓚틱슀 ìœ”íŹë ˆìŽì…˜ 우욞슝을 ìč˜ëŁŒí•˜êž° 위한 nk-1 êžží•­ì œ ìĄ°ì„±ëŹŒ 및 우욞슝 ìč˜ëŁŒì— ì‚Źìš©í•˜ëŠ” ë°©ëȕ
CN109384712B (zh) * 2017-08-14 2021-05-07 挗äșŹćźœćŽšćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž é¶ć‘nk1ć—äœ“æ‹źæŠ—ć‰‚ćŠć…¶ćœšćŒ–ç–—æ‰€è‡Žæ¶ćżƒă€ć‘•ćæȻ疗䞭的ćș”甚
WO2019038656A1 (en) 2017-08-21 2019-02-28 Leiutis Pharmaceuticals Pvt, Ltd NEW TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
HUE070000T2 (hu) * 2018-09-28 2025-04-28 Vanda Pharmaceuticals Inc Tradipitant alkalmazåsa utazåsi betegségben
JP7587215B2 (ja) * 2018-12-24 2024-11-20 ăƒŠăƒŒă‚čトラăƒȘă‚č ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ăƒȘミテッド ïŒˆăƒˆăƒŹăƒŒăƒ‡ă‚Łăƒłă‚° ケă‚ș プレă‚čă‚čラ ăƒ‹ăƒ„ăƒŒăƒ­ïŒ‰ ćŒ–ćˆç‰©ăźèŁœé€ ă€ăăźæ–°ă—ă„ćĄ©ćœąæ…‹ăŠă‚ˆăłæČ»ç™‚çš„äœżç”š
CN112174881B (zh) * 2019-07-04 2022-06-21 äžŠæ”·æŁźèŸ‰ćŒ»èŻæœ‰é™ć…Źćž äž€ç§ć„ˆćŠ„ćŒčćŠçš„èĄç”Ÿç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•
EP4017589A4 (en) * 2019-08-23 2023-09-20 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) THERAPEUTIC PROCEDURES AND THEIR APPLICATIONS
IL296635A (en) 2020-04-03 2022-11-01 Nerre Therapeutics Ltd An nk-1 receptor antagonist for the treatment of a disease selected from sepsis, septic shock, acute respiratory distress syndrome (ARDS), or multiple organ dysfunction syndrome (MODS)
JP2023531863A (ja) 2020-06-02 2023-07-26 ネッレ ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łă‚Żă‚č ăƒȘミテッド è‚șăźæ©Ÿæą°çš„æć‚·ă«ă‚ˆăŁăŠäżƒé€Čされるè‚șç·šç¶­ç—‡çŠ¶æ…‹ăźæČ»ç™‚ă§äœżç”šă™ă‚‹ăŸă‚ăźăƒ‹ăƒ„ăƒŒăƒ­ă‚­ăƒ‹ăƒłïŒˆïœŽïœ‹ïŒ‰ïŒïŒ‘ć—ćźčäœ“æ‹źæŠ—è–Ź
US12097197B2 (en) 2021-12-21 2024-09-24 Slayback Pharma Llc Stable liquid compositions of netupitant and palonosetron
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
WO2024126408A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Antioxidant-free fixed dose combination of netupitant and palonosetron
AU2023393578A1 (en) 2022-12-12 2025-07-03 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Fixed dose combination comprising netupitant and palonosetron
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1557420A (en) 1977-03-10 1979-12-12 Soc D Etudes Prod Chimique Preparation of isobutyramide derivatives
KR810001320B1 (ko) 1977-03-17 1981-10-14 삐에넎 위람 신규한 ìŽì†Œë¶€í‹°ëŒëŻžë“œë„˜ì˜ ì œìĄ°ë°©ëȕ
KR810001697B1 (ko) 1978-02-06 1981-10-27 삐에넎 위람 ìŽì†Œë¶€í‹°ëŒëŻžë“œ 유도ìČŽì˜ 신규한 ì œìĄ°ë°©ëȕ
EP0089153B1 (en) 1982-03-17 1986-09-24 Smith Kline & French Laboratories Limited Pyridine derivatives
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
GB8607313D0 (en) 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8607312D0 (en) 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
CA1339423C (en) 1988-09-14 1997-09-02 Yuji Ono Pyridine compounds and pharmaceutical use thereof
US4994456A (en) 1989-03-01 1991-02-19 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
US4973597A (en) 1989-06-30 1990-11-27 Eli Lilly And Company Anticonvulsant agents
HU207047B (en) 1989-11-07 1993-03-01 Richter Gedeon Vegyeszet Process for producing new pyridine derivatives and pharmaceutical copositions comprising same
US5364943A (en) 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
GB9021056D0 (en) 1990-09-27 1990-11-07 Pfizer Ltd Antiarrhythmic agents
GB9214120D0 (en) 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
WO1994003429A1 (en) 1992-07-31 1994-02-17 Merck Sharp & Dohme Limited Substituted amines as tachykinin receptor antagonists
US5387595A (en) 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
GB9305672D0 (en) 1993-03-19 1993-05-05 Wyeth John & Brother Ltd Amide derivatives
NZ264063A (en) 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
CA2178219C (en) * 1993-12-29 2005-03-22 Raymond Baker Substituted morpholine derivatives and their use as therapeutic agents
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
AU693898B2 (en) 1994-06-06 1998-07-09 Warner-Lambert Company Tachykinin (NK1) receptor antagonists
US6294537B1 (en) 1995-03-17 2001-09-25 Sanofi-Synthelabo Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools
EP0733632B1 (en) * 1995-03-24 2003-06-04 Takeda Chemical Industries, Ltd. Cyclic compounds, their production and use as tachykinin receptor antagonists
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
UA49006C2 (uk) 1996-03-29 2002-09-16 ЀаĐčзДр Đ†ĐœĐș. ĐŸĐŸŃ…Ń–ĐŽĐœŃ– 6-Ń„Đ”ĐœŃ–Đ»ĐżŃ–Ń€ĐžĐŽĐžĐ»-2-Đ°ĐŒŃ–ĐœŃƒ, Ń„Đ°Ń€ĐŒĐ°Ń†Đ”ĐČŃ‚ĐžŃ‡ĐœĐ° ĐșĐŸĐŒĐżĐŸĐ·ĐžŃ†Ń–Ń, ŃĐżĐŸŃŃ–Đ± Ń–ĐœĐłŃ–Đ±ŃƒĐČĐ°ĐœĐœŃ ŃĐžĐœŃ‚Đ°Đ·Đž ĐŸĐșсОЎу ĐœŃ–Ń‚Ń€ĐŸĐłĐ”ĐœŃƒ у ссаĐČціĐČ Ń‚Đ° ŃĐżĐŸŃŃ–Đ± ліĐșуĐČĐ°ĐœĐœŃ
AU4885097A (en) 1996-11-08 1998-06-03 Sankyo Company Limited Arylureas or arylmethylcarbamoyl derivatives
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
IL144717A0 (en) * 1999-02-24 2002-06-30 Hoffmann La Roche Phenyl-and pyridinyl derivatives
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
DE60006340T2 (de) * 1999-11-29 2004-09-09 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramid

Also Published As

Publication number Publication date
GT200000017A (es) 2001-08-15
FR2790473A1 (fr) 2000-09-08
ES2171109B2 (es) 2003-09-16
CY1111317T1 (el) 2015-08-05
KR20000062599A (ko) 2000-10-25
CA2299139A1 (en) 2000-08-24
US6479483B2 (en) 2002-11-12
EA200000155A3 (ru) 2000-12-25
BR0000908A (pt) 2000-09-12
AR062949A2 (es) 2008-12-17
EP1394150B1 (en) 2011-01-19
LU92745I2 (fr) 2015-08-17
DE60045564D1 (de) 2011-03-03
CA2299139C (en) 2011-03-29
FR15C0049I1 (fr) 2015-08-28
AU767048B2 (en) 2003-10-30
HK1031223A1 (en) 2001-06-08
EP1035115B1 (en) 2004-09-29
LTPA2015036I1 (lt) 2015-11-25
RS53869B1 (en) 2015-08-31
SV2002000024A (es) 2002-01-23
CY2015041I1 (el) 2016-06-22
ITMI20000328A1 (it) 2001-08-23
KR100384904B1 (ko) 2003-05-22
JP3399900B2 (ja) 2003-04-21
CZ300596B6 (cs) 2009-06-24
NL300758I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2015-12-22
ATE496032T1 (de) 2011-02-15
SE1035115T3 (sv) 2005-01-18
JO2294B1 (en) 2005-09-12
PL217311B1 (pl) 2014-07-31
JP2000247957A (ja) 2000-09-12
RS50194B (sr) 2009-05-06
NL300758I1 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2015-12-22
GEP20022676B (en) 2002-04-25
NO20000885L (no) 2000-08-25
HU0000748D0 (en) 2000-04-28
SK2352000A3 (en) 2000-09-12
UY32314A (es) 2010-02-26
SK287911B6 (sk) 2012-03-02
NO315554B1 (no) 2003-09-22
BG104187A (en) 2000-11-30
ES2359235T3 (es) 2011-05-19
US6297375B1 (en) 2001-10-02
PL338598A1 (en) 2000-08-28
DE60014216T2 (de) 2006-03-02
ZA200000894B (en) 2000-08-24
GB2347422A (en) 2000-09-06
TNSN00032A1 (fr) 2005-11-10
MY123648A (en) 2006-05-31
AR029614A1 (es) 2003-07-10
DK1035115T3 (da) 2005-01-24
CN1270959A (zh) 2000-10-25
HRP20000097A2 (en) 2001-10-31
HRP20080306A2 (en) 2008-11-30
EP1394150A1 (en) 2004-03-03
IT1320763B1 (it) 2003-12-10
TR200000520A3 (tr) 2001-06-21
CN1142144C (zh) 2004-03-17
OA11680A (fr) 2005-01-12
LTC1035115I2 (lt) 2017-04-10
BRPI0000908B8 (pt) 2021-05-25
EA200000155A2 (ru) 2000-08-28
MY147451A (en) 2012-12-14
NZ502948A (en) 2001-09-28
CY2015042I1 (el) 2016-06-22
MEP5709A (en) 2011-12-20
TWI288746B (en) 2007-10-21
NO20000885D0 (no) 2000-02-23
ES2226622T3 (es) 2005-04-01
PT1394150E (pt) 2011-02-17
BG64554B1 (bg) 2005-07-29
IL134654A (en) 2011-03-31
ES2171109A1 (es) 2002-08-16
SK287912B6 (sk) 2012-03-02
FR2790473B1 (fr) 2004-04-02
AU1946800A (en) 2000-08-31
US20020091265A1 (en) 2002-07-11
TR200000520A2 (tr) 2001-06-21
FR15C0049I2 (fr) 2016-02-12
GB0003908D0 (en) 2000-04-05
PA8491101A1 (es) 2001-04-30
DE60014216D1 (de) 2004-11-04
DE10008042A1 (de) 2000-08-31
SE1035115T5 (sv) 2015-08-04
HUP0000748A3 (en) 2003-12-29
EP1035115A1 (en) 2000-09-13
ITMI20000328A0 (it) 2000-02-23
EG23817A (en) 2007-09-19
CZ2000609A3 (cs) 2001-01-17
ME00593B (me) 2015-08-31
PT1035115E (pt) 2005-01-31
HRP20000097B1 (en) 2008-12-31
IL134654A0 (en) 2001-04-30
HU227629B1 (en) 2011-10-28
CY2015041I2 (el) 2016-06-22
ATE277905T1 (de) 2004-10-15
SI1035115T1 (en) 2005-02-28
SG91856A1 (en) 2002-10-15
RS20080562A (en) 2009-09-08
HUP0000748A2 (en) 2001-03-28
DK1394150T3 (da) 2011-03-21
MA26722A1 (fr) 2004-12-20
IS5381A (is) 2000-08-25
HRP20080306B1 (hr) 2015-01-30
UA71547C2 (uk) 2004-12-15
BR0000908B1 (pt) 2013-09-24
EA003673B1 (ru) 2003-08-28
YU9500A (sh) 2002-11-15
IS2116B (is) 2006-06-15
BE2015C057I2 (c_deeref_Disk_and_Scratch_Disk_Pools_and_Their_Defaults.html) 2019-03-06

Similar Documents

Publication Publication Date Title
PE20001467A1 (es) Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina
PE20010009A1 (es) Derivados de fenil - y piridinilo como antagonistas del receptor de la neuroquinina 1
PE20050482A1 (es) Derivados de dihidrobenzofuranilo alcanamida
PE20020258A1 (es) Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina 1 (nk-1)
PE20030238A1 (es) Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales
PE20000325A1 (es) Derivados de 2-ariletil-(piperidin-4-ilmetil)amina
PE20020721A1 (es) Derivados de quinuclidina como agentes antimuscarinicos m3
UY27029A1 (es) Nuevos derivados de pirazolpiridina sustituidos con piridina
DE69120100D1 (de) Annelierte Thiophen-Derivate, ihre Herstellung und Verwendung
PE20001551A1 (es) Derivados de eter biarilico como inhibidores de la recaptacion de monoaminas para el tratamiento de trastornos del snc
NO20053960L (no) Piperidin-benzensulfonamidderivater
BR0306208A (pt) Compostos de dibenzilamina e seu uso farmacĂȘutico
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
PE106499A1 (es) Antagonistas del receptor ccr-3
AR029616A1 (es) Compuestos derivados de 3-fenil-piridina, su uso, un proceso para prepararlos y medicamentos que los contienen
PE20000170A1 (es) Derivados benzosulfonas
DE69838662D1 (de) Morphinanderivate und ihre medizinische Anwendung
PE20020657A1 (es) Derivados de amida de piperidinas 1,4-disustituidas de formula (i)
ES2113081T3 (es) 1,4-benzotiazepinas utiles como agentes neurologicos.
PE20011114A1 (es) Decahidro-isoquinolinas
PE20040772A1 (es) Composicion y actividad antiviral de derivados de piperazina azaindoloxoaceticos
PE20030761A1 (es) Derivados del 7-amino-benzotiazol
PE20040757A1 (es) Derivados de benzoxazina
ES2154605A1 (es) Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3
JO2235B1 (en) Derivatives of phenyl

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term